Numerous studies have confirmed that S100A10 is an oncogene, such as intestinal cancer (Suzuki et al., 2011), basal-type breast cancer (McKiernan et al., 2011), lung cancer (Katono et al., 2016), ovarian cancer (Wang et al., 2019b), pancreatic ductal cancer (Bydoun et al., 2018), and gastric cancer (El-Rifai et al., 2002). Here, S100A10 is linked to breast cancer.